Effect of histamine-H2-receptor antagonists on the exocrine pancreatic secretion.
Pancreatic exocrine secretion has been studied in 10 patients with documented duodenal ulcer before and after 4 weeks of cimetidine treatment (1 g/die). This chronic 'short term' cimetidine administration did not result in any substantial modification of exo-pancreatic response stimulated by Secretin and Caerulein. From this point of view the drug could be employed in the treatment of pancreatic insufficiency in order to obtain a better utilization of pancreatic enzyme supplement. It is, however, questionable if such a 'long-term' therapy may be responsible for the appearance or the relapse of a peptic ulcer.
D000328:Adult; D002108:Ceruletide / Q000494:pharmacology; D002927:Cimetidine / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism; D010189:Pancreatic Juice / Q000378:metabolism*; D012633:Secretin / Q000494:pharmacology
D006635:Histamine H2 Antagonists; D012633:Secretin; D002927:Cimetidine; D002108:Ceruletide